DDR1 and cancer: Nishiota et al. [28] reported a series of hydantoin-type compounds (e.g., 20 and 21) that were very potent inhibitors of DDR1 (IC50s 1 and 3 nM, respectively), with suggested utility in cancer, kidney disease, or fibrosis.